Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FaReWell Depression - a randomized controlled trial of a physiotherapeutic program for the facial rehabilitation of wellbeing in depression.

Frontiers in psychiatry·2026
Same author

[The own and the foreign. Philosophical and clinical aspects].

Therapeutische Umschau. Revue therapeutique·2023
Same author

Effects of glabellar botulinum toxin injections on resting-state functional connectivity in borderline personality disorder.

European archives of psychiatry and clinical neuroscience·2023
Same author

Neuronal effects of glabellar botulinum toxin injections using a valenced inhibition task in borderline personality disorder.

Scientific reports·2022
Same author

Clinical effects of glabellar botulinum toxin injections on borderline personality disorder: A randomized controlled trial.

Journal of psychopharmacology (Oxford, England)·2022
Same author

Postmarketing safety surveillance data reveals protective effects of botulinum toxin injections against incident anxiety.

Scientific reports·2021
Same journal

[Multimodal Cardiac Imaging: New Developments for Clinical Practice].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Coronary angiography: From cardiac catheterization to advanced interventional cardiovascular imaging].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Athlete's heart: role of cardiac imaging in the prevention of sudden cardiac death].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Multimodal imaging in cardiac amyloidosis and cardiac sarcoidosis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Inflammatory Heart Disease: The Role of Multimodality Cardiac Imaging in Myocarditis and Pericarditis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

State-of-the-Art Cardiac Imaging

Therapeutische Umschau. Revue therapeutique·2026
See all related articles

Related Experiment Videos

[Antidementia drugs].

Franz Müller-Spahn1, Daniel Sollberger, M Axel Wollmer

  • 1Universitäre Psychiatrische Kliniken Basel, Basel. franz.mueller-spahn@upkbs.ch

Therapeutische Umschau. Revue Therapeutique
|June 5, 2009
PubMed
Summary
This summary is machine-generated.

Current dementia treatments focus on symptom management, not cures. New therapies target beta-amyloid and tau proteins for Alzheimer's disease (AD), while existing drugs like acetylcholine esterase inhibitors (AchEI) and memantine offer symptomatic relief for AD and vascular dementia.

Related Experiment Videos

Area of Science:

  • Neurology
  • Pharmacology
  • Geriatrics

Context:

  • Dementia, including Alzheimer's disease (AD) and vascular dementia, significantly impacts cognitive function, daily living, and behavior.
  • Current therapeutic strategies primarily aim to manage symptoms rather than provide a cure, with treatment goals evolving based on disease progression.

Purpose:

  • To review current pharmacological and non-pharmacological treatment approaches for dementia.
  • To discuss emerging therapeutic strategies targeting beta-amyloid and tau pathways for Alzheimer's disease.
  • To evaluate the efficacy and limitations of existing treatments for various dementia types.

Summary:

  • Pharmacological treatments for dementia aim to improve cognitive function, daily activities, and behavioral symptoms, with varying efficacy depending on disease stage and type.
  • Acetylcholine esterase inhibitors (AchEI) and memantine are established treatments for mild-to-severe Alzheimer's disease and show some benefit in vascular dementia.
  • Novel therapeutic approaches for AD focus on targeting beta-amyloid and tau metabolism, including immunisation strategies, while non-pharmacological interventions are crucial and require individualized adaptation.

Impact:

  • Highlights the current limitations in dementia treatment, emphasizing the need for causal therapies.
  • Underscores the importance of a multimodal treatment approach, integrating pharmacological and non-pharmacological strategies.
  • Informs clinical practice regarding the judicious use of existing medications and the potential of emerging therapies for dementia management.